EP2576587A4 - Proteines ngal mutantes et leurs utilisations - Google Patents

Proteines ngal mutantes et leurs utilisations

Info

Publication number
EP2576587A4
EP2576587A4 EP11787264.8A EP11787264A EP2576587A4 EP 2576587 A4 EP2576587 A4 EP 2576587A4 EP 11787264 A EP11787264 A EP 11787264A EP 2576587 A4 EP2576587 A4 EP 2576587A4
Authority
EP
European Patent Office
Prior art keywords
mutant ngal
ngal proteins
proteins
mutant
ngal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP11787264.8A
Other languages
German (de)
English (en)
Other versions
EP2576587B1 (fr
EP2576587A1 (fr
Inventor
Jonathan Barasch
Andong Qiu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University in the City of New York
Original Assignee
Columbia University in the City of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia University in the City of New York filed Critical Columbia University in the City of New York
Publication of EP2576587A1 publication Critical patent/EP2576587A1/fr
Publication of EP2576587A4 publication Critical patent/EP2576587A4/fr
Application granted granted Critical
Publication of EP2576587B1 publication Critical patent/EP2576587B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP11787264.8A 2010-05-24 2011-05-24 Proteines ngal mutantes et leurs utilisations Active EP2576587B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34758710P 2010-05-24 2010-05-24
US35497310P 2010-06-15 2010-06-15
PCT/US2011/037774 WO2011149962A1 (fr) 2010-05-24 2011-05-24 Proteines ngal mutantes et leurs utilisations

Publications (3)

Publication Number Publication Date
EP2576587A1 EP2576587A1 (fr) 2013-04-10
EP2576587A4 true EP2576587A4 (fr) 2014-11-05
EP2576587B1 EP2576587B1 (fr) 2018-03-21

Family

ID=45004337

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11787264.8A Active EP2576587B1 (fr) 2010-05-24 2011-05-24 Proteines ngal mutantes et leurs utilisations

Country Status (5)

Country Link
US (4) US9534027B2 (fr)
EP (1) EP2576587B1 (fr)
JP (1) JP2013529907A (fr)
ES (1) ES2667066T3 (fr)
WO (1) WO2011149962A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011149962A1 (fr) 2010-05-24 2011-12-01 The Trustees Of Columbia University In The City Of New York Proteines ngal mutantes et leurs utilisations
EP2791684B1 (fr) 2011-12-12 2017-08-23 Pieris Pharmaceuticals GmbH Méthodes de prévention ou de traitement de troubles par l'augmentation de la biodisponibilité du fer et formulation pharmaceutique associée
US9522940B2 (en) 2012-05-23 2016-12-20 Pieris Pharmaceuticals Gmbh Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3
EP2925337B1 (fr) 2012-11-21 2019-07-03 The Trustees of Columbia University in the City of New York Protéines ngal mutantes et leurs utilisations
WO2015095553A1 (fr) * 2013-12-20 2015-06-25 Nephrogenesis, Llc Procédés et appareils de dialyse rénale
CN104314976B (zh) * 2014-11-14 2017-01-11 北京石油化工学院 一种两自由度内转子永磁偏置球形径向磁轴承
AU2016205886A1 (en) * 2015-01-07 2017-08-03 Nottingham University Hospitals Nhs Trust Biomarkers related to kidney function and methods involving their use
JP6843754B2 (ja) 2015-02-18 2021-03-17 ピエリス ファーマシューティカルズ ゲーエムベーハー ピオベルジン及びピオケリンに特異的な新規なタンパク質
EP3298029A1 (fr) 2015-05-18 2018-03-28 Pieris Pharmaceuticals GmbH Mutéines de la lipocaline 2 humaine avec affinité pour glypican-3 (gpc3)
EP3115371A1 (fr) * 2015-07-07 2017-01-11 Sanofi Molécules de fusion
EP4215204A1 (fr) * 2022-01-24 2023-07-26 Universitat Pompeu Fabra Lipocaline humaine associée à la gélatinase neutrophilique dérivée de bactéries recombinantes et son utilisation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080095782A1 (en) * 2006-10-20 2008-04-24 The University Of Hong Kong Use of lipocalin-2 as a diagnostic marker and therapeutic target
WO2010033847A1 (fr) * 2008-09-18 2010-03-25 The Trustees Of Columbia University In The City Of New York Sidérophores se liant à ngal et utilisation de ceux-ci pour traiter une carence en fer et une surcharge en fer

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4640909A (en) 1985-05-07 1987-02-03 J. T. Baker Chemical Company Bonded phase of silica and carboalkoxyalkyl silanes for solid phase extraction
US6825037B1 (en) 1991-02-08 2004-11-30 University Of Vermont Recombinant transferrins, transferrin half-molecules and mutants thereof
SE9401351D0 (sv) 1994-04-21 1994-04-21 Venge A method for diagnosis
US5627034A (en) 1995-12-05 1997-05-06 Wisconsin Alumni Research Foundation Assay for carcinoma proliferative status by measuring NGAL expression level
ATE243513T1 (de) 1996-05-01 2003-07-15 Gen Hospital Corp Wachstumshemmung und abtoetung solider tumore unter verwendung eines prolaktin-modulators und eines photosensitizers
US6498142B1 (en) 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
EA004402B1 (ru) 1996-05-24 2004-04-29 Байоджен, Инк. Модуляторы регенерации тканей
US5985830A (en) 1996-09-16 1999-11-16 Dalhousie University Use of IGF-I for the treatment of kidney disorders
WO1998041226A1 (fr) 1997-03-18 1998-09-24 Roche Diagnostics Gmbh Preparations pharmaceutiques associees contenant de l'erythropoietine et preparations a base de fer
US6492325B1 (en) 1998-05-22 2002-12-10 Boys Town National Research Hospital Use of α1β1 integrin receptor inhibitors and TGF-β1 inhibitors in the treatment of kidney disease
AUPP784398A0 (en) 1998-12-21 1999-01-21 Monash University Kidney disease detection and treatment
US6114123A (en) 1999-06-14 2000-09-05 Incyte Pharmaceuticals, Inc. Lipocalin family protein
US20050201981A1 (en) 2004-03-10 2005-09-15 Chih-Ping Liu Method of optimizing treatment with interferon-tau
US7235520B2 (en) * 2000-09-21 2007-06-26 University Of Massachusetts Method of inducing apoptosis in lymphoid cells
AU1169702A (en) 2000-10-13 2002-04-22 Childrens Medical Center Non-invasive enzyme screen for tissue remodelling-associated conditions
AU2002305394A1 (en) 2001-05-04 2002-11-18 Biosite, Inc. Diagnostic markers of acute coronary syndromes and methods of use thereof
WO2003029462A1 (fr) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteines de la lipocaline neutrophile humaine associee a la gelatinase et de proteines apparentees
GB0215509D0 (en) 2002-07-04 2002-08-14 Novartis Ag Marker genes
AU2003247303A1 (en) 2002-07-17 2004-02-02 Index Pharmaceuticals Ab Antisense compounds, methods and compositions for treating ngal-related inflammatory disorders
US20180153889A1 (en) 2002-10-30 2018-06-07 Bach Pharma, Inc. Modulation of cell fates and activities by phthalazinediones
US7191068B2 (en) 2003-03-25 2007-03-13 Proteogenix, Inc. Proteomic analysis of biological fluids
US8068990B2 (en) 2003-03-25 2011-11-29 Hologic, Inc. Diagnosis of intra-uterine infection by proteomic analysis of cervical-vaginal fluids
JP5392980B2 (ja) 2003-03-27 2014-01-22 チルドレンズ ホスピタル メディカル センター 早発型の腎尿細管細胞障害を検出するための方法およびキット
WO2005052125A2 (fr) 2003-11-21 2005-06-09 University Of Massachusetts Recepteurs de 24p3 et utilisations correspondantes
US20050272101A1 (en) 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
WO2005107793A2 (fr) 2004-05-06 2005-11-17 The Trustees Of Columbia University Ngal pour la reduction et l'amelioration des lesions ischemiques et nephrotoxiques
US7423238B2 (en) 2004-05-12 2008-09-09 Illinois Tool Works Inc. Gas system for wire feeding devices
US7141382B1 (en) 2004-10-12 2006-11-28 Parikh Chirag R Methods for detection of IL-18 as an early marker for diagnosis of acute renal failure and predictor of mortality
PL1831699T3 (pl) 2004-12-20 2010-04-30 Antibodyshop As Oznaczanie lipokaliny neutrofilowej związanej z żelatynazą (NGAL) jako markera diagnostycznego dla zaburzeń nerek
US20080050832A1 (en) 2004-12-23 2008-02-28 Buechler Kenneth F Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
WO2006078717A2 (fr) 2005-01-19 2006-07-27 Beth Israel Deaconess Medical Center Lipocaline 2 pour traiter, prevenir et maitriser les metastases cancereuses, l'angiogenese et la fibrose
KR100681763B1 (ko) 2005-02-28 2007-02-15 재단법인 목암생명공학연구소 인간 리포칼린 2를 유효성분으로 포함하는 암 전이 억제용약학적 조성물, 이를 이용한 암 전이 억제 방법
US20070037232A1 (en) 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
CA2614935A1 (fr) 2005-07-21 2007-02-01 The Johns Hopkins University Insuffisance renale aigue
WO2007041623A2 (fr) 2005-10-03 2007-04-12 Biosite Incorporated Methodes et compositions utiles dans le diagnostic et/ou le pronostic des syndromes de reponse inflammatoire systemique
US20080090304A1 (en) 2006-10-13 2008-04-17 Barasch Jonathan Matthew Diagnosis and monitoring of chronic renal disease using ngal
WO2007117330A2 (fr) 2005-12-22 2007-10-18 Biosite Incorporated Criblages de la protéine c latente et leurs usages pour le diagnostic et/ou le pronostic de syndromes de réponse inflammatoire systémique
TW200726845A (en) 2006-01-02 2007-07-16 Nat Defense Medical Ct Biomarker molecular of renal illness and detecting method for the same
WO2007098102A2 (fr) 2006-02-17 2007-08-30 Children's Medical Center Corporation Ngal libre en tant que biomarqueur de cancer
EP2924440A3 (fr) 2006-06-07 2016-03-09 Health Diagnostic Laboratory, Inc. Marqueurs associés à des événements artériovasculaires et procédés d'utilisation de ceux-ci
US20090298073A1 (en) 2006-06-30 2009-12-03 Gerhold David L Kidney Toxicity Biomarkers
US20100189643A1 (en) 2006-07-24 2010-07-29 Duke University Drug delivery with stimulus responsive biopolymers
EP2095107B1 (fr) 2006-11-14 2014-07-02 Alere San Diego, Inc. Procédés de prévoir les risques
NZ579994A (en) 2007-03-15 2011-09-30 Univ Florida Desferrithiocin polyether analogues useful in the treatment of pathological conditions responsive to chelation or sequestration of trivalent metal
EP2479571A3 (fr) 2007-03-26 2012-09-26 Novartis AG Biomarqueurs de sécurité rénale prédictive et signatures de biomarqueur pour surveiller la fonction rénale
JP4956292B2 (ja) 2007-06-25 2012-06-20 パナソニック株式会社 情報セキュリティ装置およびカウンタ制御方法
JP5766947B2 (ja) 2007-09-07 2015-08-19 チルドレンズ ホスピタル メディカル センター 臨床サンプルにおける分泌性のルイス抗原およびシアル化抗原のレベルの疾患リスクの予測指標としての使用
US20090082443A1 (en) 2007-09-17 2009-03-26 Purac Biochem B.V. Use of fatty acid esters of glycerol combined with polylysine against gram-negative bacteria
US20090123970A1 (en) 2007-10-19 2009-05-14 Abbott Laboratories Glycosylated mammalian ngal and use thereof
US20090269777A1 (en) 2007-10-19 2009-10-29 Abbott Laboratories Immunoassays and kits for the detection of ngal
US20090124572A1 (en) 2007-11-09 2009-05-14 Deanna Jean Nelson Iron-containing nutritional supplement
WO2009108762A2 (fr) 2008-02-26 2009-09-03 The Penn State Research Foundation Méthodes et compositions de traitement de pathologies sensibles aux rétinoïdes
US8592170B2 (en) 2008-03-12 2013-11-26 The Trustees Of Columbia University In The City Of New York High molecular weight Ngal as a biomarker for chronic kidney disease
AU2009264214B2 (en) * 2008-06-24 2013-06-06 Technische Universitaet Muenchen Muteins of hNGAL and related proteins with affinity for a given target
US20100122355A1 (en) 2008-07-16 2010-05-13 Neal Paragas Transgenic Reporter Mouse and Method for Use
US20120083421A1 (en) 2008-10-16 2012-04-05 The Trustees Of Columbia University In The City Of New York Use of urinary ngal to diagnose and monitor hiv-associated nephropathy (hivan)
WO2010045585A2 (fr) 2008-10-16 2010-04-22 The Trustees Of Columbia University In The City Of New York Utilisation de ngal urinaire pour diagnostiquer et surveiller une néphropathie associée au vih (hivan)
US20100105150A1 (en) 2008-10-24 2010-04-29 Abbott Laboratories Isolated human autoantibodies to neutrophil gelatinase-associated lipocalin (ngal) and methods and kits for the detection of human autoantibodies to ngal
WO2010057184A2 (fr) 2008-11-17 2010-05-20 The Brigham And Women's Hospital, Inc. Procédés pour la détection de lésion rénale aiguë chez des humains
US20100233739A1 (en) 2009-02-12 2010-09-16 Jonathan Barasch Use of urinary ngal to diagnose unilateral and bilateral urinary obstruction
US20100233740A1 (en) 2009-02-12 2010-09-16 Jonathan Barasch Use of urinary ngal to distinguish kidney disease and predict mortality in subjects with cirrhosis
US20120214177A1 (en) 2009-06-17 2012-08-23 The Trustees Of Columbia University In The City Of New York Methods and compositions for diagnosis of urosepsis and urinary tract infection
WO2011053832A1 (fr) 2009-10-29 2011-05-05 The Trustees Of Columbia University In The City Of New York Utilisation de la protéine ngal urinaire à des fins de diagnostic d'une septicémie chez des bébés de très petit poids de naissance
MX2009012633A (es) 2009-11-23 2011-05-24 Univ Mexico Nacional Autonoma Metodo de diagnostico para detectar la lesion renal aguda a traves del uso de la proteina de choque termico de 72 kda como un biomarcador sensible.
WO2011140554A1 (fr) 2010-05-07 2011-11-10 The Trustees Of Columbia University In The City Of New York Ngal et infections urinaires
US20100234765A1 (en) 2010-05-21 2010-09-16 Barasch Jonathan Matthew Diagnosis and monitoring of chronic renal disease using ngal
WO2011149962A1 (fr) 2010-05-24 2011-12-01 The Trustees Of Columbia University In The City Of New York Proteines ngal mutantes et leurs utilisations
AU2011290751B2 (en) 2010-08-16 2015-08-13 Pieris Ag Binding proteins for Hepcidin
EP2622095B1 (fr) 2010-10-01 2016-09-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes de prédiction de la progression et méthodes de traitement d'une maladie rénale chronique chez un patient
WO2012068545A1 (fr) 2010-11-18 2012-05-24 Jonathan Barasch Ngal et insuffisance rénale aiguë
EP2925337B1 (fr) * 2012-11-21 2019-07-03 The Trustees of Columbia University in the City of New York Protéines ngal mutantes et leurs utilisations
KR102234623B1 (ko) 2013-05-22 2021-04-02 알닐람 파마슈티칼스 인코포레이티드 Ｔｍｐｒｓｓ6 조성물 및 이의 사용 방법
WO2015142882A1 (fr) 2014-03-18 2015-09-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Procédés pour le diagnostic de pathologies associées au fer
US9578541B2 (en) 2015-04-06 2017-02-21 At&T Intellectual Property I, L.P. Proximity based sub-pooling of network devices in mobile wireless networks

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080095782A1 (en) * 2006-10-20 2008-04-24 The University Of Hong Kong Use of lipocalin-2 as a diagnostic marker and therapeutic target
WO2010033847A1 (fr) * 2008-09-18 2010-03-25 The Trustees Of Columbia University In The City Of New York Sidérophores se liant à ngal et utilisation de ceux-ci pour traiter une carence en fer et une surcharge en fer

Also Published As

Publication number Publication date
US20130217637A1 (en) 2013-08-22
US10588937B2 (en) 2020-03-17
US20210038686A1 (en) 2021-02-11
US9534027B2 (en) 2017-01-03
ES2667066T3 (es) 2018-05-09
US11730790B2 (en) 2023-08-22
EP2576587B1 (fr) 2018-03-21
US20230414709A1 (en) 2023-12-28
US20170189482A1 (en) 2017-07-06
EP2576587A1 (fr) 2013-04-10
WO2011149962A1 (fr) 2011-12-01
JP2013529907A (ja) 2013-07-25

Similar Documents

Publication Publication Date Title
HUS2100032I1 (hu) Helyettesített 5-fluor-1H-pirazolopiridin-származékok és alkalmazásuk
IL222961A0 (en) Novel dna-dinding proteins and uses thereof
EP2576587A4 (fr) Proteines ngal mutantes et leurs utilisations
EP2593469A4 (fr) Protéines et polypeptides modifiés et leurs utilisations
HK1187049A1 (en) Bisaryl-bonded aryltriazolones and use thereof
SG184289A1 (en) Novel peptides and methods for their preparation and use
HUE057004T2 (hu) CD277 elleni antitestek és alkalmazásaik
SI2552434T1 (sl) Peptidi in njih uporaba
HK1179981A1 (zh) 的抗體及其用途
PL2588491T3 (pl) Nowy peptyd i jego zastosowanie
EP2593595A4 (fr) Nouveaux peptides et leurs utilisations
EP2632952A4 (fr) Anticorps anti-sod1 et utilisations de ceux-ci
EP2558500A4 (fr) Protéines qui se lient à pi16 et leurs utilisations
EP2608785A4 (fr) Lipomacrocycles et leurs utilisations
HK1168622A1 (en) Antigen peptide and use thereof
AU2011259204A1 (en) Antigen peptide and use thereof
AU2011259204A8 (en) Antigen peptide and use thereof
EP2554552A4 (fr) Nouvel anticorps anti-cd98 et son utilisation
EP2925337A4 (fr) Protéines ngal mutantes et leurs utilisations
EP2660249A4 (fr) Dérivé peptidique et son utilisation
EP2620449A4 (fr) Anticorps dirigé contre l'éphrine b2 et utilisation correspondante
GB2478399B (en) Toner compositions and methods
EP2578682A4 (fr) Anticorps et son utilisation
EP2545378A4 (fr) Anticorps anti-lg3 et leurs utilisations
GB201019361D0 (en) Biosensor and uses thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20121217

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20141007

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 1/00 20060101AFI20140930BHEP

17Q First examination report despatched

Effective date: 20160615

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20171116

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 980947

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180415

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602011046746

Country of ref document: DE

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2667066

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20180509

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 8

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20180321

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180321

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180621

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180321

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180321

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180321

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 980947

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180321

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180622

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180321

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180321

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180321

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180621

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180321

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180321

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180321

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180321

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180321

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180321

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180321

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180321

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180321

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180723

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602011046746

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20180531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180321

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180321

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

26N No opposition filed

Effective date: 20190102

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180531

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180524

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180524

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180321

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180524

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180321

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20110524

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180321

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180721

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230314

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20230626

Year of fee payment: 13

Ref country code: DE

Payment date: 20230626

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20230620

Year of fee payment: 13

Ref country code: GB

Payment date: 20230627

Year of fee payment: 13

Ref country code: ES

Payment date: 20230703

Year of fee payment: 13